Montelukast does not prevent reactive airway disease in young children hospitalized for RSV bronchiolitis
Aim: To evaluate the long‐term effect of montelukast on symptoms of cough and wheeze following RSV bronchiolitis. Methods: Fifty eight patients (aged ≤ 24 months) hospitalized with a first episode of RSV bronchiolitis were enrolled in this double blind prospective randomized trial comparing montel...
Gespeichert in:
| Veröffentlicht in: | Acta Paediatrica 2009-11, Vol.98 (11), p.1830-1834 |
|---|---|
| Hauptverfasser: | , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 1834 |
|---|---|
| container_issue | 11 |
| container_start_page | 1830 |
| container_title | Acta Paediatrica |
| container_volume | 98 |
| creator | Proesmans, M Sauer, K Govaere, E Raes, M De Bilderling, G De Boeck, K |
| description | Aim: To evaluate the long‐term effect of montelukast on symptoms of cough and wheeze following RSV bronchiolitis.
Methods: Fifty eight patients (aged ≤ 24 months) hospitalized with a first episode of RSV bronchiolitis were enrolled in this double blind prospective randomized trial comparing montelukast (n = 31) vs placebo (n = 27).
Results: During the 3‐month treatment period, there were no statistical significant differences between the two groups for symptom‐free days and nights (48.5 [interquartile range 33.0.0–66.0] for montelukast vs 57.0 [29.0–71.0] for placebo p = 0.415) nor disease‐free days and nights (44.5 days [26.0–54.0] vs 53.0 [22.3–71.0]; p = 0.266). During the 1 year follow‐up, there were 41 exacerbations in the montelukast group vs 54 exacerbations in the placebo group (p = 0.57). Time to first exacerbation was not different. Number of unscheduled visits and need to start inhaled steroids were comparable in the two groups.
Conclusion: Treatment with montelukast after hospital admission for RSV bronchiolitis in children younger than 2 years of age did not reduce symptoms of cough and wheeze. We cannot exclude that a subgroup of children may, however, benefit from this treatment. |
| doi_str_mv | 10.1111/j.1651-2227.2009.01463.x |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_734074939</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>734074939</sourcerecordid><originalsourceid>FETCH-LOGICAL-c4363-f16707d428be720679f0063ed64a79c045b070c0c04709121d29a0f02c8960343</originalsourceid><addsrcrecordid>eNqNkE1v1DAQhi0EokvhLyBfEKeE8Ufs9YHDqoW2onxDy83yJhPqbTZe7KTd5deTkNVyxT54JD_vzOghhDLI2XBerXKmCpZxznXOAUwOTCqRbx-Q2eHjIZnBHERW8EIckScprQC4MFI9JkfMqGKoxIz496HtsOlvXepoFTDRNnR0E_EO245GdGXn75A6H-_djlY-oUtIfUt3oW9_0vLGN1XElt6EtPGda_xvrGgdIv3y9YouY2gHIjS-8-kpeVS7JuGz_XtMvr998-3kPLv8eHZxsrjMSimUyGqmNOhK8vkSNQelTQ2gBFZKOm1KkMUSNJTDlRoM46zixkENvJwbBUKKY_Jy6ruJ4VePqbNrn0psGtdi6JPVQoKWRpiBnE9kGUNKEWu7iX7t4s4ysKNnu7KjTjvqtKNn-9ez3Q7R5_sh_XKN1b_gXuwAvNgDLpWuqaNrS58OHB-6aW7GbV9P3L1vcPffC9jFpwWb5mRT3qcOt4e8i7dWaaELe_3hzJ5-fnf948pIeyr-AOs1p-Y</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>734074939</pqid></control><display><type>article</type><title>Montelukast does not prevent reactive airway disease in young children hospitalized for RSV bronchiolitis</title><source>MEDLINE</source><source>Access via Wiley Online Library</source><source>Alma/SFX Local Collection</source><creator>Proesmans, M ; Sauer, K ; Govaere, E ; Raes, M ; De Bilderling, G ; De Boeck, K</creator><creatorcontrib>Proesmans, M ; Sauer, K ; Govaere, E ; Raes, M ; De Bilderling, G ; De Boeck, K</creatorcontrib><description>Aim: To evaluate the long‐term effect of montelukast on symptoms of cough and wheeze following RSV bronchiolitis.
Methods: Fifty eight patients (aged ≤ 24 months) hospitalized with a first episode of RSV bronchiolitis were enrolled in this double blind prospective randomized trial comparing montelukast (n = 31) vs placebo (n = 27).
Results: During the 3‐month treatment period, there were no statistical significant differences between the two groups for symptom‐free days and nights (48.5 [interquartile range 33.0.0–66.0] for montelukast vs 57.0 [29.0–71.0] for placebo p = 0.415) nor disease‐free days and nights (44.5 days [26.0–54.0] vs 53.0 [22.3–71.0]; p = 0.266). During the 1 year follow‐up, there were 41 exacerbations in the montelukast group vs 54 exacerbations in the placebo group (p = 0.57). Time to first exacerbation was not different. Number of unscheduled visits and need to start inhaled steroids were comparable in the two groups.
Conclusion: Treatment with montelukast after hospital admission for RSV bronchiolitis in children younger than 2 years of age did not reduce symptoms of cough and wheeze. We cannot exclude that a subgroup of children may, however, benefit from this treatment.</description><identifier>ISSN: 0803-5253</identifier><identifier>EISSN: 1651-2227</identifier><identifier>DOI: 10.1111/j.1651-2227.2009.01463.x</identifier><identifier>PMID: 19659463</identifier><language>eng</language><publisher>Oxford, UK: Blackwell Publishing Ltd</publisher><subject>Acetates - pharmacology ; Acetates - therapeutic use ; Biological and medical sciences ; Bronchiolitis ; Bronchiolitis, Viral - drug therapy ; Bronchodilator Agents - pharmacology ; Bronchodilator Agents - therapeutic use ; Chi-Square Distribution ; Cough ; Cough - drug therapy ; Double-Blind Method ; Follow-Up Studies ; General aspects ; Hospitalization ; Human viral diseases ; Humans ; Infant ; Infectious diseases ; LTRA ; Medical sciences ; Montelukast ; Prevention and actions ; Prospective Studies ; Public health. Hygiene ; Public health. Hygiene-occupational medicine ; Quinolines - pharmacology ; Quinolines - therapeutic use ; Respiratory Hypersensitivity - prevention & control ; Respiratory Sounds - drug effects ; Respiratory Syncytial Virus Infections - drug therapy ; Respiratory Syncytial Virus, Human - drug effects ; RSV ; Statistics, Nonparametric ; Treatment Outcome ; Viral diseases ; Viral diseases of the respiratory system and ent viral diseases ; Wheeze</subject><ispartof>Acta Paediatrica, 2009-11, Vol.98 (11), p.1830-1834</ispartof><rights>2009 The Author(s)/Journal Compilation © 2009 Foundation Acta Pædiatrica</rights><rights>2009 INIST-CNRS</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c4363-f16707d428be720679f0063ed64a79c045b070c0c04709121d29a0f02c8960343</citedby><cites>FETCH-LOGICAL-c4363-f16707d428be720679f0063ed64a79c045b070c0c04709121d29a0f02c8960343</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://onlinelibrary.wiley.com/doi/pdf/10.1111%2Fj.1651-2227.2009.01463.x$$EPDF$$P50$$Gwiley$$H</linktopdf><linktohtml>$$Uhttps://onlinelibrary.wiley.com/doi/full/10.1111%2Fj.1651-2227.2009.01463.x$$EHTML$$P50$$Gwiley$$H</linktohtml><link.rule.ids>314,780,784,1417,27924,27925,45574,45575</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=22007294$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/19659463$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Proesmans, M</creatorcontrib><creatorcontrib>Sauer, K</creatorcontrib><creatorcontrib>Govaere, E</creatorcontrib><creatorcontrib>Raes, M</creatorcontrib><creatorcontrib>De Bilderling, G</creatorcontrib><creatorcontrib>De Boeck, K</creatorcontrib><title>Montelukast does not prevent reactive airway disease in young children hospitalized for RSV bronchiolitis</title><title>Acta Paediatrica</title><addtitle>Acta Paediatr</addtitle><description>Aim: To evaluate the long‐term effect of montelukast on symptoms of cough and wheeze following RSV bronchiolitis.
Methods: Fifty eight patients (aged ≤ 24 months) hospitalized with a first episode of RSV bronchiolitis were enrolled in this double blind prospective randomized trial comparing montelukast (n = 31) vs placebo (n = 27).
Results: During the 3‐month treatment period, there were no statistical significant differences between the two groups for symptom‐free days and nights (48.5 [interquartile range 33.0.0–66.0] for montelukast vs 57.0 [29.0–71.0] for placebo p = 0.415) nor disease‐free days and nights (44.5 days [26.0–54.0] vs 53.0 [22.3–71.0]; p = 0.266). During the 1 year follow‐up, there were 41 exacerbations in the montelukast group vs 54 exacerbations in the placebo group (p = 0.57). Time to first exacerbation was not different. Number of unscheduled visits and need to start inhaled steroids were comparable in the two groups.
Conclusion: Treatment with montelukast after hospital admission for RSV bronchiolitis in children younger than 2 years of age did not reduce symptoms of cough and wheeze. We cannot exclude that a subgroup of children may, however, benefit from this treatment.</description><subject>Acetates - pharmacology</subject><subject>Acetates - therapeutic use</subject><subject>Biological and medical sciences</subject><subject>Bronchiolitis</subject><subject>Bronchiolitis, Viral - drug therapy</subject><subject>Bronchodilator Agents - pharmacology</subject><subject>Bronchodilator Agents - therapeutic use</subject><subject>Chi-Square Distribution</subject><subject>Cough</subject><subject>Cough - drug therapy</subject><subject>Double-Blind Method</subject><subject>Follow-Up Studies</subject><subject>General aspects</subject><subject>Hospitalization</subject><subject>Human viral diseases</subject><subject>Humans</subject><subject>Infant</subject><subject>Infectious diseases</subject><subject>LTRA</subject><subject>Medical sciences</subject><subject>Montelukast</subject><subject>Prevention and actions</subject><subject>Prospective Studies</subject><subject>Public health. Hygiene</subject><subject>Public health. Hygiene-occupational medicine</subject><subject>Quinolines - pharmacology</subject><subject>Quinolines - therapeutic use</subject><subject>Respiratory Hypersensitivity - prevention & control</subject><subject>Respiratory Sounds - drug effects</subject><subject>Respiratory Syncytial Virus Infections - drug therapy</subject><subject>Respiratory Syncytial Virus, Human - drug effects</subject><subject>RSV</subject><subject>Statistics, Nonparametric</subject><subject>Treatment Outcome</subject><subject>Viral diseases</subject><subject>Viral diseases of the respiratory system and ent viral diseases</subject><subject>Wheeze</subject><issn>0803-5253</issn><issn>1651-2227</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2009</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqNkE1v1DAQhi0EokvhLyBfEKeE8Ufs9YHDqoW2onxDy83yJhPqbTZe7KTd5deTkNVyxT54JD_vzOghhDLI2XBerXKmCpZxznXOAUwOTCqRbx-Q2eHjIZnBHERW8EIckScprQC4MFI9JkfMqGKoxIz496HtsOlvXepoFTDRNnR0E_EO245GdGXn75A6H-_djlY-oUtIfUt3oW9_0vLGN1XElt6EtPGda_xvrGgdIv3y9YouY2gHIjS-8-kpeVS7JuGz_XtMvr998-3kPLv8eHZxsrjMSimUyGqmNOhK8vkSNQelTQ2gBFZKOm1KkMUSNJTDlRoM46zixkENvJwbBUKKY_Jy6ruJ4VePqbNrn0psGtdi6JPVQoKWRpiBnE9kGUNKEWu7iX7t4s4ysKNnu7KjTjvqtKNn-9ez3Q7R5_sh_XKN1b_gXuwAvNgDLpWuqaNrS58OHB-6aW7GbV9P3L1vcPffC9jFpwWb5mRT3qcOt4e8i7dWaaELe_3hzJ5-fnf948pIeyr-AOs1p-Y</recordid><startdate>200911</startdate><enddate>200911</enddate><creator>Proesmans, M</creator><creator>Sauer, K</creator><creator>Govaere, E</creator><creator>Raes, M</creator><creator>De Bilderling, G</creator><creator>De Boeck, K</creator><general>Blackwell Publishing Ltd</general><general>Blackwell</general><scope>BSCLL</scope><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>200911</creationdate><title>Montelukast does not prevent reactive airway disease in young children hospitalized for RSV bronchiolitis</title><author>Proesmans, M ; Sauer, K ; Govaere, E ; Raes, M ; De Bilderling, G ; De Boeck, K</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c4363-f16707d428be720679f0063ed64a79c045b070c0c04709121d29a0f02c8960343</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2009</creationdate><topic>Acetates - pharmacology</topic><topic>Acetates - therapeutic use</topic><topic>Biological and medical sciences</topic><topic>Bronchiolitis</topic><topic>Bronchiolitis, Viral - drug therapy</topic><topic>Bronchodilator Agents - pharmacology</topic><topic>Bronchodilator Agents - therapeutic use</topic><topic>Chi-Square Distribution</topic><topic>Cough</topic><topic>Cough - drug therapy</topic><topic>Double-Blind Method</topic><topic>Follow-Up Studies</topic><topic>General aspects</topic><topic>Hospitalization</topic><topic>Human viral diseases</topic><topic>Humans</topic><topic>Infant</topic><topic>Infectious diseases</topic><topic>LTRA</topic><topic>Medical sciences</topic><topic>Montelukast</topic><topic>Prevention and actions</topic><topic>Prospective Studies</topic><topic>Public health. Hygiene</topic><topic>Public health. Hygiene-occupational medicine</topic><topic>Quinolines - pharmacology</topic><topic>Quinolines - therapeutic use</topic><topic>Respiratory Hypersensitivity - prevention & control</topic><topic>Respiratory Sounds - drug effects</topic><topic>Respiratory Syncytial Virus Infections - drug therapy</topic><topic>Respiratory Syncytial Virus, Human - drug effects</topic><topic>RSV</topic><topic>Statistics, Nonparametric</topic><topic>Treatment Outcome</topic><topic>Viral diseases</topic><topic>Viral diseases of the respiratory system and ent viral diseases</topic><topic>Wheeze</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Proesmans, M</creatorcontrib><creatorcontrib>Sauer, K</creatorcontrib><creatorcontrib>Govaere, E</creatorcontrib><creatorcontrib>Raes, M</creatorcontrib><creatorcontrib>De Bilderling, G</creatorcontrib><creatorcontrib>De Boeck, K</creatorcontrib><collection>Istex</collection><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Acta Paediatrica</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Proesmans, M</au><au>Sauer, K</au><au>Govaere, E</au><au>Raes, M</au><au>De Bilderling, G</au><au>De Boeck, K</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Montelukast does not prevent reactive airway disease in young children hospitalized for RSV bronchiolitis</atitle><jtitle>Acta Paediatrica</jtitle><addtitle>Acta Paediatr</addtitle><date>2009-11</date><risdate>2009</risdate><volume>98</volume><issue>11</issue><spage>1830</spage><epage>1834</epage><pages>1830-1834</pages><issn>0803-5253</issn><eissn>1651-2227</eissn><abstract>Aim: To evaluate the long‐term effect of montelukast on symptoms of cough and wheeze following RSV bronchiolitis.
Methods: Fifty eight patients (aged ≤ 24 months) hospitalized with a first episode of RSV bronchiolitis were enrolled in this double blind prospective randomized trial comparing montelukast (n = 31) vs placebo (n = 27).
Results: During the 3‐month treatment period, there were no statistical significant differences between the two groups for symptom‐free days and nights (48.5 [interquartile range 33.0.0–66.0] for montelukast vs 57.0 [29.0–71.0] for placebo p = 0.415) nor disease‐free days and nights (44.5 days [26.0–54.0] vs 53.0 [22.3–71.0]; p = 0.266). During the 1 year follow‐up, there were 41 exacerbations in the montelukast group vs 54 exacerbations in the placebo group (p = 0.57). Time to first exacerbation was not different. Number of unscheduled visits and need to start inhaled steroids were comparable in the two groups.
Conclusion: Treatment with montelukast after hospital admission for RSV bronchiolitis in children younger than 2 years of age did not reduce symptoms of cough and wheeze. We cannot exclude that a subgroup of children may, however, benefit from this treatment.</abstract><cop>Oxford, UK</cop><pub>Blackwell Publishing Ltd</pub><pmid>19659463</pmid><doi>10.1111/j.1651-2227.2009.01463.x</doi><tpages>5</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0803-5253 |
| ispartof | Acta Paediatrica, 2009-11, Vol.98 (11), p.1830-1834 |
| issn | 0803-5253 1651-2227 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_734074939 |
| source | MEDLINE; Access via Wiley Online Library; Alma/SFX Local Collection |
| subjects | Acetates - pharmacology Acetates - therapeutic use Biological and medical sciences Bronchiolitis Bronchiolitis, Viral - drug therapy Bronchodilator Agents - pharmacology Bronchodilator Agents - therapeutic use Chi-Square Distribution Cough Cough - drug therapy Double-Blind Method Follow-Up Studies General aspects Hospitalization Human viral diseases Humans Infant Infectious diseases LTRA Medical sciences Montelukast Prevention and actions Prospective Studies Public health. Hygiene Public health. Hygiene-occupational medicine Quinolines - pharmacology Quinolines - therapeutic use Respiratory Hypersensitivity - prevention & control Respiratory Sounds - drug effects Respiratory Syncytial Virus Infections - drug therapy Respiratory Syncytial Virus, Human - drug effects RSV Statistics, Nonparametric Treatment Outcome Viral diseases Viral diseases of the respiratory system and ent viral diseases Wheeze |
| title | Montelukast does not prevent reactive airway disease in young children hospitalized for RSV bronchiolitis |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-27T00%3A20%3A36IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Montelukast%20does%20not%20prevent%20reactive%20airway%20disease%20in%20young%20children%20hospitalized%20for%20RSV%20bronchiolitis&rft.jtitle=Acta%20Paediatrica&rft.au=Proesmans,%20M&rft.date=2009-11&rft.volume=98&rft.issue=11&rft.spage=1830&rft.epage=1834&rft.pages=1830-1834&rft.issn=0803-5253&rft.eissn=1651-2227&rft_id=info:doi/10.1111/j.1651-2227.2009.01463.x&rft_dat=%3Cproquest_cross%3E734074939%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=734074939&rft_id=info:pmid/19659463&rfr_iscdi=true |